Eli Lilly and Company (NYSE:LLY) Trading Up 7% – Here’s Why

Posted by Brenda Bartman on Jun 26th, 2026

Eli Lilly and Company logo Eli Lilly and Company (NYSE:LLY – Get Free Report)’s share price rose 7% during trading on Friday . The company traded as high as $1,215.76 and last traded at $1,206.51. Approximately 7,686,279 shares traded hands during mid-day trading, an increase of 138% from the average daily volume of 3,233,765 shares. The stock had previously closed at $1,127.69.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: The European Medicines Agency’s CHMP recommended Jaypirca (pirtobrutinib) for approval in the EU for adults with chronic lymphocytic leukemia across all lines of therapy, which could expand international sales and broaden the drug’s addressable market. Article Title
Positive Sentiment: Investors are also reacting to Lilly’s Medicare GLP-1 Bridge program, which could improve access to obesity treatments like Zepbound and Foundayo for eligible Medicare Part D patients starting July 1, supporting demand visibility for a key growth franchise. Article Title
Positive Sentiment: Recent headlines also point to continued enthusiasm around Lilly’s obesity and diabetes pipeline, including analyst commentary calling it a top momentum name and reports that the company remains a leader in the weight-loss drug race. Article Title
Neutral Sentiment: Lilly updated its ongoing Alzheimer’s study to test annual dosing of donanemab, a development that adds to the long-term pipeline story but does not yet change the near-term financial outlook. Article Title
Neutral Sentiment: The company also launched its cancer drug Tanstrive in India, which is a constructive commercial step but likely a smaller driver than the obesity and EU regulatory news. Article Title
Negative Sentiment: At least one recent note downgraded the stock on valuation, arguing Lilly still has an excellent pipeline but that the current entry point is less attractive after the sharp run-up. Article Title

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on LLY shares. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a report on Thursday, May 21st. Bank of America lifted their price objective on Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the stock a “buy” rating in a report on Tuesday, May 26th. Cantor Fitzgerald reissued an “overweight” rating on shares of Eli Lilly and Company in a research report on Monday. Morgan Stanley restated an “overweight” rating on shares of Eli Lilly and Company in a research note on Friday, June 5th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and set a $1,283.00 price target on shares of Eli Lilly and Company in a report on Friday, May 22nd. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,235.07.

Check Out Our Latest Report on LLY

Eli Lilly and Company Trading Up 7.0%

The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The stock has a market capitalization of $1.14 trillion, a PE ratio of 42.86, a P/E/G ratio of 1.22 and a beta of 0.53. The stock has a 50 day moving average price of $1,030.27 and a 200-day moving average price of $1,019.65.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. During the same quarter in the prior year, the business earned $3.34 EPS. The business’s quarterly revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Sell-side analysts expect that Eli Lilly and Company will post 35.8 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s payout ratio is presently 24.58%.

Institutional Investors Weigh In On Eli Lilly and Company

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LLY. Maryland Capital Advisors Inc. bought a new position in shares of Eli Lilly and Company in the fourth quarter worth approximately $25,000. Osbon Capital Management LLC purchased a new position in shares of Eli Lilly and Company during the 4th quarter valued at $25,000. Basso Capital Management L.P. purchased a new position in shares of Eli Lilly and Company during the 4th quarter valued at $30,000. Miller Global Investments LLC bought a new position in Eli Lilly and Company in the 4th quarter worth $33,000. Finally, E Fund Management Hong Kong Co. Ltd. boosted its holdings in Eli Lilly and Company by 342.9% in the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock worth $32,000 after buying an additional 24 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

About Eli Lilly and Company

(Get Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.